MX2020013623A - Composicion inmunogenica. - Google Patents

Composicion inmunogenica.

Info

Publication number
MX2020013623A
MX2020013623A MX2020013623A MX2020013623A MX2020013623A MX 2020013623 A MX2020013623 A MX 2020013623A MX 2020013623 A MX2020013623 A MX 2020013623A MX 2020013623 A MX2020013623 A MX 2020013623A MX 2020013623 A MX2020013623 A MX 2020013623A
Authority
MX
Mexico
Prior art keywords
incapable
commensal bacterium
immunogenic composition
carrying
engineered bacteriophage
Prior art date
Application number
MX2020013623A
Other languages
English (en)
Inventor
Christiane Marie- Paule Simone Jeanne Feron
Sandra Giannini
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020013623A publication Critical patent/MX2020013623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención describe un bacteriófago manipulado capaz de unirse a una bacteria comensal e insertar su polinucleótido genómico en la bacteria comensal, pero incapaz de producir progenie, incapaz de llevar a cabo un ciclo lisogénico e incapaz de llevar a cabo un ciclo lítico dentro de la bacteria comensal, en donde el bacteriófago manipulado comprende un polinucleótido genómico que incluye al menos un gen que codifica al menos un antígeno o antígenos heterólogos bajo el control de un promotor.
MX2020013623A 2018-06-19 2019-06-18 Composicion inmunogenica. MX2020013623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862686889P 2018-06-19 2018-06-19
PCT/EP2019/065974 WO2019243307A1 (en) 2018-06-19 2019-06-18 Immunogenic composition

Publications (1)

Publication Number Publication Date
MX2020013623A true MX2020013623A (es) 2021-03-25

Family

ID=67314722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013623A MX2020013623A (es) 2018-06-19 2019-06-18 Composicion inmunogenica.

Country Status (8)

Country Link
US (1) US20210252081A1 (es)
EP (1) EP3810163A1 (es)
JP (1) JP7426953B2 (es)
CN (1) CN112703006A (es)
BR (1) BR112020024514A2 (es)
CA (1) CA3102353A1 (es)
MX (1) MX2020013623A (es)
WO (1) WO2019243307A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
GB202015255D0 (en) * 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses
EP4240843A1 (en) * 2020-11-04 2023-09-13 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781175B2 (en) 1999-04-09 2005-05-12 Intercell Usa, Inc. Recombinant toxin A/toxin B vaccine against Clostridium Difficile
CA2463827C (en) 2003-04-17 2013-10-15 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Methods and compositions for controlled release of bioactive compounds
EP1618886A1 (en) * 2004-07-20 2006-01-25 Fonds zur Förderung der Forschung auf dem Gebiet der molekularen Virologie und Gentherapie Bacteriophage and prophage proteins in cancer gene therapy
US8309077B2 (en) 2004-11-02 2012-11-13 Chr. Hansen A/S Stabilized bacteriophage formulations
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
EA030898B1 (ru) * 2011-05-27 2018-10-31 Глаксосмитклайн Байолоджикалс С.А. ПОЛИПЕПТИД ДЛЯ ИНДУКЦИИ НЕЙТРАЛИЗУЮЩИХ АНТИТЕЛ ПРОТИВ ТОКСИНА А И ТОКСИНА B Clostridium difficile И КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТОТ ПОЛИПЕПТИД
WO2014045226A1 (en) 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US20160250283A1 (en) 2013-10-23 2016-09-01 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
LT3160500T (lt) 2014-06-25 2019-10-25 Glaxosmithkline Biologicals Sa Clostridium difficile imunogeninė kompozicija
GB201600075D0 (en) * 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
CN107670023B (zh) * 2017-10-10 2021-10-22 中国科学院武汉病毒研究所 V12cbd蛋白及其编码基因的一种新用途

Also Published As

Publication number Publication date
JP2021529514A (ja) 2021-11-04
JP7426953B2 (ja) 2024-02-02
CA3102353A1 (en) 2019-12-26
WO2019243307A1 (en) 2019-12-26
CN112703006A (zh) 2021-04-23
BR112020024514A2 (pt) 2021-03-02
US20210252081A1 (en) 2021-08-19
EP3810163A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MX2020013623A (es) Composicion inmunogenica.
EP3708660A3 (en) Polypeptides
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2018016114A (es) Una novedosa fructosa-6-fosfato-3-epimerasa termoestable y un procedimiento para producir alulosa mediante el uso de la misma.
MX2021003306A (es) Metodos y composiciones para mejorar la solubilizacion de fosfato.
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MY156849A (en) Novel lactobacillus plantarum and composition comprising the same
MY197415A (en) Functional expression of monooxygenase and methods of use
MX2016003944A (es) Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos.
MX2018001820A (es) Bifidobacterium longum.
MX2015014720A (es) Mutante de epimerasa psicosa y metodo para preparar psicosa mediante el uso del mismo.
PH12017502215A1 (en) Recombinant microorganism for improve production of fine chemicals
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MY189932A (en) Recombinant microorganism for improved production of alanine
PH12017501678A1 (en) Recombinant microorganism for improved production of finie chemicals
NZ702839A (en) Vaccine and methods to reduce campylobacter infection
WO2017132332A8 (en) Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
SA518391787B1 (ar) تركيبة لعلاج متلازمة كريغلر نجار
MY188944A (en) Microbial production of fatty diols
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
PH12019500264A1 (en) Lactobacillus salivarius cjls1511, animal feed additive composition comprising same bacterium or dead cells thereof, and method for producing same dead cells
MX2017015213A (es) Producto sanguineo universal y metodos para preparar y usar el mismo.
MX2022000778A (es) Proteina quimerica l1 del virus de papiloma humano.
PH12018500069A1 (en) Novel lactobacillus sp. microorganisms, and composition for animal feed comprising same
PL409332A1 (pl) Szczepy Enterococcus faecalis do produkcji monoklonalnych preparatów fagowych